Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 7/20 | 0.62 |
| ▸ | NOS1 | P29475 | 12/20 | 0.51 |
| ▸ | NOS3 | P29474 | 11/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7568588 | 0.87 | QRFPR (0.69) | QRFPRNOS1NOS3NOS2 | |
| SCHEMBL7600919 | 0.86 | NOS1 (0.54) | QRFPRNOS1NOS3KCNH2NOS2 | |
| SCHEMBL7971736 | 0.85 | QRFPR (0.61) | QRFPRNOS1NOS3KCNH2NOS2 | |
| Hydrochloric Acid SCHEMBL7598807 | 0.84 | QRFPR (0.60) | QRFPRNOS1NOS3KCNH2NOS2 | |
| SCHEMBL7973642 | 0.83 | QRFPR (0.67) | QRFPRNOS1NOS3NOS2 | |
| SCHEMBL7565608 | 0.83 | QRFPR (0.66) | QRFPRNOS1NOS3KCNH2NOS2 | |
| SCHEMBL7598794 | 0.83 | NOS3 (0.50) | QRFPRNOS1NOS3KCNH2NOS2 | |
| Hydrochloric Acid SCHEMBL7562296 | 0.82 | QRFPR (0.66) | QRFPRNOS1NOS3KCNH2 | |
| SCHEMBL7597204 | 0.82 | NOS1 (0.49) | QRFPRNOS1NOS3KCNH2NOS2 | |
| Hydrochloric Acid SCHEMBL7566303 | 0.82 | QRFPR (0.65) | QRFPRNOS1NOS3KCNH2NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | claimed |
| WO-2001046171-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001046171-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | NOS1, NOS2, NOS3 | QRFPR 1455/4885NOS1 1/4885NOS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.